» Articles » PMID: 33879765

Cross-sectional Investigation of Insulin Resistance in Youths with Autism Spectrum Disorder. Any Role for Reduced Brain Glucose Metabolism?

Overview
Date 2021 Apr 21
PMID 33879765
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The autism spectrum disorder (ASD) is an etiologically heterogeneous disorder. Dysfunctions of the intermediate metabolism have been described in some patients. We speculate these metabolic abnormalities are associated with brain insulin resistance (IR), i.e., the reduced glucose metabolism at the level of the nervous central system. The Homeostasis model assessment of insulin resistance (HOMA-IR) is very often used in population studies as estimate of peripheral IR and it has been recently recognized as proxy of brain IR. We investigated HOMA-IR in 60 ASD patients aged 4-18 years and 240 healthy controls, also aged 4-18 years, but unmatched for age, sex, body weight, or body mass index (BMI). At multivariable linear regression model, the HOMA-IR was 0.31 unit higher in ASD individuals than in controls, after having adjusted for sex, age, BMI z-score category, and lipids that are factors known to influence HOMA-IR. Findings of this preliminary study suggest it is worth investigating brain glucose metabolism in larger population of patients with ASD by using gold standard technique. The recognition of a reduced glucose metabolism in some areas of the brain as marker of autism might have tremendous impact on our understanding of the pathogenic mechanisms of the disease and in terms of public health.

Citing Articles

Intranasal Insulin Eases Autism in Rats via GDF-15 and Anti-Inflammatory Pathways.

Arda D, Tunc K, Bozkurt M, Bora E, Cigel A, Erbas O Curr Issues Mol Biol. 2024; 46(9):10530-10544.

PMID: 39329976 PMC: 11431515. DOI: 10.3390/cimb46090624.


Validation of plasma protein glycation and oxidation biomarkers for the diagnosis of autism.

Al-Saei A, Nour-Eldine W, Rajpoot K, Arshad N, Al-Shammari A, Kamal M Mol Psychiatry. 2023; 29(3):653-659.

PMID: 38135754 PMC: 11153128. DOI: 10.1038/s41380-023-02357-9.


Hypometabolism, Alzheimer's Disease, and Possible Therapeutic Targets: An Overview.

Raut S, Bhalerao A, Powers M, Gonzalez M, Mancuso S, Cucullo L Cells. 2023; 12(16).

PMID: 37626828 PMC: 10453773. DOI: 10.3390/cells12162019.


Dietary recommendations to customize canteen menus according to the nutritional and sensory needs of individuals with autism spectrum disorder.

Conti M, Breda C, Basilico S, Luzzi A, Voto L, Santero S Eat Weight Disord. 2023; 28(1):66.

PMID: 37526770 PMC: 10393838. DOI: 10.1007/s40519-023-01590-z.


MeCP2 Is an Epigenetic Factor That Links DNA Methylation with Brain Metabolism.

Vuu Y, Roberts C, Rastegar M Int J Mol Sci. 2023; 24(4).

PMID: 36835623 PMC: 9966807. DOI: 10.3390/ijms24044218.


References
1.
Shapiro A, Wilkening G, Aalborg J, Ringham B, Glueck D, Tregellas J . Childhood Metabolic Biomarkers Are Associated with Performance on Cognitive Tasks in Young Children. J Pediatr. 2019; 211:92-97. PMC: 6661005. DOI: 10.1016/j.jpeds.2019.03.043. View

2.
Mohammad-Rezazadeh I, Frohlich J, Loo S, Jeste S . Brain connectivity in autism spectrum disorder. Curr Opin Neurol. 2016; 29(2):137-47. PMC: 4843767. DOI: 10.1097/WCO.0000000000000301. View

3.
Mitelman S, Bralet M, Haznedar M, Hollander E, Shihabuddin L, Hazlett E . Positron emission tomography assessment of cerebral glucose metabolic rates in autism spectrum disorder and schizophrenia. Brain Imaging Behav. 2017; 12(2):532-546. PMC: 5648637. DOI: 10.1007/s11682-017-9721-z. View

4.
Koepsell H, Vallon V . A special issue on glucose transporters in health and disease. Pflugers Arch. 2020; 472(9):1107-1109. PMC: 7484381. DOI: 10.1007/s00424-020-02442-w. View

5.
Ziats M, Comeaux M, Yang Y, Scaglia F, Elsea S, Sun Q . Improvement of regressive autism symptoms in a child with TMLHE deficiency following carnitine supplementation. Am J Med Genet A. 2015; 167A(9):2162-7. DOI: 10.1002/ajmg.a.37144. View